[go: up one dir, main page]

MA26595A1 - Composes hypolipidemiants de benzothiazepine - Google Patents

Composes hypolipidemiants de benzothiazepine

Info

Publication number
MA26595A1
MA26595A1 MA25421A MA25421A MA26595A1 MA 26595 A1 MA26595 A1 MA 26595A1 MA 25421 A MA25421 A MA 25421A MA 25421 A MA25421 A MA 25421A MA 26595 A1 MA26595 A1 MA 26595A1
Authority
MA
Morocco
Prior art keywords
hypolipidemian
benzothiazepine
compounds
hypolipidemian compounds
Prior art date
Application number
MA25421A
Other languages
English (en)
Inventor
Louis Handlon Anthony
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26595A1 publication Critical patent/MA26595A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA25421A 1998-01-10 1999-01-07 Composes hypolipidemiants de benzothiazepine MA26595A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9800428.6A GB9800428D0 (en) 1998-01-10 1998-01-10 Chemical compounds

Publications (1)

Publication Number Publication Date
MA26595A1 true MA26595A1 (fr) 2004-12-20

Family

ID=10825042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25421A MA26595A1 (fr) 1998-01-10 1999-01-07 Composes hypolipidemiants de benzothiazepine

Country Status (27)

Country Link
US (1) US6465451B1 (fr)
EP (1) EP1045840A1 (fr)
JP (1) JP2002500220A (fr)
KR (1) KR20010033988A (fr)
CN (1) CN1292785A (fr)
AP (1) AP2000001860A0 (fr)
AR (1) AR014261A1 (fr)
AU (1) AU2515599A (fr)
BR (1) BR9906799A (fr)
CA (1) CA2317651A1 (fr)
CO (1) CO4820391A1 (fr)
EA (1) EA200000623A1 (fr)
GB (1) GB9800428D0 (fr)
HR (1) HRP20000468A2 (fr)
HU (1) HUP0201343A3 (fr)
ID (1) ID25495A (fr)
IL (1) IL137040A0 (fr)
IS (1) IS5551A (fr)
MA (1) MA26595A1 (fr)
NO (1) NO20003514L (fr)
NZ (1) NZ505453A (fr)
PE (1) PE20000179A1 (fr)
PL (1) PL341672A1 (fr)
SK (1) SK10242000A3 (fr)
TR (1) TR200001816T2 (fr)
WO (1) WO1999035135A1 (fr)
ZA (1) ZA9981B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
JP2002533413A (ja) * 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびフィブリン酸誘導体の組み合わせ
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
EP1465885A4 (fr) 2002-01-17 2005-04-27 Pharmacia Corp Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
FR2849024B1 (fr) * 2002-12-20 2007-11-02 Aventis Pharma Sa Nouveaux composes chiraux derives d'esters de l'acide hexanoique, procede et intermediaires de preparation, utilisation a la synthese de l'acide 2-(bromomethyl)2-ethyl hexanoique chiral
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP3593802A3 (fr) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires
BR112013010157B1 (pt) 2010-11-04 2020-02-04 Albireo Ab iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
EP3413878B1 (fr) 2016-02-09 2021-04-14 Albireo AB Formulation orale de cholestyramine et utilisation associée
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750944C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3071182A1 (fr) 2017-08-09 2019-02-14 Albireo Ab Pastilles de cholestyramine, formulations orales de cholestyramine et leur utilisation
EP3664781A1 (fr) 2017-08-09 2020-06-17 Albireo AB Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (fr) 2018-06-05 2023-01-18 Albireo AB Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
PT3810581T (pt) 2018-06-20 2025-03-05 Albireo Ab Modificações cristalinas de odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
AU2020218908B2 (en) 2019-02-06 2025-01-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3127408A1 (fr) 2019-02-06 2020-08-13 Albireo Ab Composes de benzothiazepine et leur utilisation en tant que modulateurs de l'acide biliaire
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
HUE065571T2 (hu) 2019-12-04 2024-06-28 Albireo Ab Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként
WO2021110886A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs de l'acide biliaire
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
CA3158181A1 (fr) 2019-12-04 2021-06-10 Albireo Ab Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
CN114786773B (zh) * 2019-12-04 2024-10-18 阿尔比里奥公司 苯并硫杂氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
MX2022006731A (es) * 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
CA3186857A1 (fr) 2020-08-03 2022-02-10 Per-Goran Gillberg Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
WO2025146508A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire
WO2025146507A1 (fr) 2024-01-05 2025-07-10 Albireo Ab Composés de benzothia(di)azépine et leur utilisation en tant que modulateurs d'acide biliaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09501915A (ja) * 1993-08-06 1997-02-25 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体アンタゴニスト
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines

Also Published As

Publication number Publication date
CA2317651A1 (fr) 1999-07-15
SK10242000A3 (sk) 2001-02-12
EP1045840A1 (fr) 2000-10-25
NO20003514L (no) 2000-09-07
IL137040A0 (en) 2001-06-14
CO4820391A1 (es) 1999-07-28
NZ505453A (en) 2002-11-26
IS5551A (is) 2000-06-27
HRP20000468A2 (en) 2000-10-31
AR014261A1 (es) 2001-02-07
ID25495A (id) 2000-10-05
NO20003514D0 (no) 2000-07-07
HUP0201343A3 (en) 2003-08-28
ZA9981B (en) 2000-07-06
US6465451B1 (en) 2002-10-15
CN1292785A (zh) 2001-04-25
GB9800428D0 (en) 1998-03-04
EA200000623A1 (ru) 2001-04-23
JP2002500220A (ja) 2002-01-08
PL341672A1 (en) 2001-04-23
WO1999035135A1 (fr) 1999-07-15
AP2000001860A0 (en) 2000-09-30
BR9906799A (pt) 2000-10-10
HUP0201343A2 (hu) 2003-06-28
AU2515599A (en) 1999-07-26
TR200001816T2 (tr) 2000-11-21
PE20000179A1 (es) 2000-03-16
KR20010033988A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
MA26595A1 (fr) Composes hypolipidemiants de benzothiazepine
PT945132E (pt) Composicao de ibuprofeno
ID27092A (id) Pembuatan ftalat anhidrida
FR09C0030I2 (fr) Composes thrombopoietiques
IS2325B (is) Örgerðar samsetningar epleróns
PT1032396E (pt) Esterilizacao de glucocorticoesteroides
DE69907405D1 (de) Optischer mehrkomponentenkörper
ATE229954T1 (de) Betacarbolinverbindungen
PT930302E (pt) Derivados de benzo-sulfona
ID28266A (id) Senyawa-senyawa amidin
PT1119430E (pt) Fresa
PT1104422E (pt) Derivados de fenilxantina
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
PT928790E (pt) Derivados de tiazolo
NO20005006L (no) Kalsilytiske forbindelser
EP1087957A4 (fr) Composes auto-inducteurs
EP1106626A4 (fr) Preparation de glycopeptides ordinaires
PT1056716E (pt) Derivados de ciclo-hexanodiolo
DK1155050T3 (da) Fremstilling af polyolefin
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
DE59909413D1 (de) Karosseriebauteil
FI980222A0 (fi) Stycke av isoleringsaemne med en genomgaoende primaerstroemledning
PT1060183E (pt) Derivados de 5'-desoxicitidina
PT1123283E (pt) Derivados de tiazole
DE59909114D1 (de) Armschiene